TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announced that it has sold and installed its SteraMist Hybrid System at a private research university on the East Coast. The contract is the company’s second SteraMist Hybrid System sale within a $13 million pipeline for automated installation projects, underscoring the growing demand for its ionized hydrogen peroxide (iHP) technology in high‑stakes medical environments.
The university will use the system to sterilize reusable medical equipment destined for patient homes, a critical step that requires stringent safety protocols. By providing consumables and service support, the deal creates a recurring revenue stream that helps TOMI transition from lumpy equipment sales to a more predictable razor‑blade model, a strategic priority highlighted by the company’s management team.
TOMI’s recent financials illustrate the context of this win. In Q3 2025 the company generated $2 million in revenue and recorded a net loss of $450,000. In 2024 revenue was $7.74 million, a modest 5.23% increase, but net losses rose 31.6%. The company’s market capitalization was approximately $16.27 million as of January 6 2026. The new contract adds to the recurring revenue base that is central to TOMI’s long‑term growth strategy.
The $13 million pipeline for automated installations reflects TOMI’s focus on scaling its iHP solutions across hospitals, biosafety labs, and pharmaceutical manufacturing sites. This second sale demonstrates that the company’s technology is not only effective but also commercially viable, reinforcing confidence in the pipeline’s projected value and the company’s ability to secure additional contracts with academic and medical institutions.
COO Elissa J. Shane said, “The SteraMist Hybrid System was the ideal solution for this deployment, and we are discussing further installations within the university. The fact that this research university has integrated this system to meet their stringent operational needs validates iHP as the superior, reliable choice for high‑stakes medical product sterilization.” Her comments highlight the company’s confidence in its technology and its potential to expand within the same client base.
The contract’s significance lies in both the validation of iHP technology and the creation of a recurring revenue stream that supports TOMI’s shift toward a predictable business model. While the company continues to face financial challenges, the deal signals momentum in a key market segment and positions TOMI to pursue additional high‑value contracts in the healthcare and life‑sciences arena.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.